[go: up one dir, main page]

WO2008156614A3 - Imidazopyrazines as protein kinase inhibitors - Google Patents

Imidazopyrazines as protein kinase inhibitors Download PDF

Info

Publication number
WO2008156614A3
WO2008156614A3 PCT/US2008/007295 US2008007295W WO2008156614A3 WO 2008156614 A3 WO2008156614 A3 WO 2008156614A3 US 2008007295 W US2008007295 W US 2008007295W WO 2008156614 A3 WO2008156614 A3 WO 2008156614A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
imidazopyrazines
protein kinase
kinase inhibitors
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/007295
Other languages
French (fr)
Other versions
WO2008156614A2 (en
Inventor
Tao Yu
David B Belanger
Angela D Kerekes
Zhaoyang Meng
Jayaram R Tagat
Sara J Esposite
Amit K Mandal
Yushi Xiao
Bheemashankar A Kulkarni
Yonglian Zhang
Patrick J Curran
Ronald Doll
M Arshad Siddiqui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40002934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008156614(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Priority to EP08768351A priority Critical patent/EP2170892A2/en
Priority to MX2009013729A priority patent/MX2009013729A/en
Priority to JP2010512177A priority patent/JP2010529195A/en
Priority to CN200880101960A priority patent/CN101772500A/en
Priority to CA2690557A priority patent/CA2690557A1/en
Publication of WO2008156614A2 publication Critical patent/WO2008156614A2/en
Publication of WO2008156614A3 publication Critical patent/WO2008156614A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or Aurora kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or Aurora kinases using such compounds or pharmaceutical compositions.
PCT/US2008/007295 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors Ceased WO2008156614A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08768351A EP2170892A2 (en) 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors
MX2009013729A MX2009013729A (en) 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors.
JP2010512177A JP2010529195A (en) 2007-06-14 2008-06-11 Imidazopyrazine as an inhibitor of protein kinase
CN200880101960A CN101772500A (en) 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors
CA2690557A CA2690557A1 (en) 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94399907P 2007-06-14 2007-06-14
US60/943,999 2007-06-14
US98793207P 2007-11-14 2007-11-14
US60/987,932 2007-11-14

Publications (2)

Publication Number Publication Date
WO2008156614A2 WO2008156614A2 (en) 2008-12-24
WO2008156614A3 true WO2008156614A3 (en) 2009-02-12

Family

ID=40002934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007295 Ceased WO2008156614A2 (en) 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors

Country Status (10)

Country Link
EP (1) EP2170892A2 (en)
JP (1) JP2010529195A (en)
CN (1) CN101772500A (en)
AR (1) AR066958A1 (en)
CA (1) CA2690557A1 (en)
CL (1) CL2008001745A1 (en)
MX (1) MX2009013729A (en)
PE (1) PE20090365A1 (en)
TW (1) TW200911811A (en)
WO (1) WO2008156614A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119264A1 (en) 2009-04-16 2010-10-21 Centro Nacional De Investigaciones Oncólogicas (Cnio) Imidazopyrazines for use as kinase inhibitors
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
US9199999B2 (en) * 2010-06-01 2015-12-01 Bayer Intellectual Property Gmbh Substituted imidazopyrazines
ES2541054T3 (en) * 2010-10-20 2015-07-15 Université De Bordeaux Signatures of the clinical outcome in gastrointestinal stromal tumors and method of treatment of gastrointestinal stromal tumors
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
EP2714681B1 (en) 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (en) 2012-07-09 2017-10-20 詹森药业有限公司 The inhibitor of phosphodiesterase 10
AU2015205374B2 (en) 2014-01-13 2018-08-23 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
HUE046273T2 (en) 2014-02-13 2020-02-28 Incyte Corp Cyclopropylamines as LSD1 Inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SMT201900620T1 (en) 2014-02-13 2020-01-14 Incyte Corp Cyclopropylamines as lsd1 inhibitors
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
CN107660205B (en) 2015-04-03 2021-08-27 因赛特公司 Heterocyclic compounds as LSD1 inhibitors
HUE070538T2 (en) 2015-08-12 2025-06-28 Incyte Holdings Corp Salts of an lsd1 inhibitor
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
RS64411B1 (en) * 2017-03-31 2023-09-29 Aurigene Oncology Ltd Compounds and compositions for treating hematological disorders
CN107954977A (en) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 The synthetic method of Raltitrexed intermediate
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
MA55147A (en) 2018-11-21 2021-09-29 Univ Texas COMPOSITIONS AND METHODS FOR MODULATING SHORT CHAIN DEHYDROGENASE ACTIVITY
JP7771084B2 (en) * 2020-04-29 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー Antibacterial 8-phenylamino-3-(pyrazol-4-yl)imidazo[1,2-a]pyrazine derivatives
EP4178571A4 (en) * 2020-07-10 2024-07-17 The Regents Of The University Of Michigan GAS41 INHIBITORS AND THEIR METHODS OF USE
KR20240004476A (en) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 Combination therapy for cancer treatment
WO2022222995A1 (en) * 2021-04-23 2022-10-27 南京明德新药研发有限公司 Picolinamide compound
CN116715668A (en) * 2022-03-07 2023-09-08 上海凌达生物医药有限公司 Nitrogen-containing heterocyclic cell cycle inhibitor compound, preparation method and application
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026877A1 (en) * 2002-09-23 2004-04-01 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
WO2006053121A2 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2007058942A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2007058873A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as cyclin depentend kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026877A1 (en) * 2002-09-23 2004-04-01 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
WO2006053121A2 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2007058942A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2007058873A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as cyclin depentend kinase inhibitors

Also Published As

Publication number Publication date
AR066958A1 (en) 2009-09-23
CN101772500A (en) 2010-07-07
EP2170892A2 (en) 2010-04-07
MX2009013729A (en) 2010-01-25
CL2008001745A1 (en) 2008-12-05
JP2010529195A (en) 2010-08-26
CA2690557A1 (en) 2008-12-24
WO2008156614A2 (en) 2008-12-24
PE20090365A1 (en) 2009-04-04
TW200911811A (en) 2009-03-16

Similar Documents

Publication Publication Date Title
WO2008156614A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2010088368A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2008057512A3 (en) Imidazopyrazines as protein kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2008045266A3 (en) Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor
WO2007044449A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007058873A3 (en) Imidazopyrazines as cyclin depentend kinase inhibitors
MX2009011355A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors.
WO2007044426A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2008045268A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2007044401A3 (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2008045267A3 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2005077954A3 (en) Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2007079164A3 (en) Protein kinase inhibitors
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
WO2007011962A3 (en) Treatment of cancer
WO2007084557A3 (en) Azaindoles useful as inhibitors of janus kinases
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
WO2005116025A3 (en) 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
WO2008079521A3 (en) Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880101960.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768351

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2690557

Country of ref document: CA

Ref document number: 2010512177

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/013729

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008768351

Country of ref document: EP